This high resolution study from Germany aims at extending available population-based survival data, which were mostly restricted to age- and stage-specific estimates in the past by further prognostic cancer characteristics such as tumor grade, HR status and HER2/neu expression. The gene discussed is ERBB2; the disease is neoplasm.